STAT3 and cancer: NFkB, Notch and S1PR1 signaling are also positive regulators of IL 6 expression and are frequently co-expressedwith activated STAT3 in cancers, whereas the aberrant signaling of other "oncogenic" pathways such as EGFR, HER2, Ras and Rho can also result in increased IL-6 production and subsequent STAT3 activation [3].